Given the heterogeneity and rarity of inborn errors of immunity (IEIs), management guidelines that deal with primary immunodeficiency as a whole are rare. The most recent general guideline, the ...
Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first Phase III study of an in vivo CRISPR therapy. In this large-scale, double-blind trial, 80 ...
Primary immunodeficiency (PI) is a group of more than 400 disorders that affect the immune system. In people with PI, the immune system is weakened or missing important components, making it harder ...
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results